Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group.
Clear guidance helps doctors safely use modern eczema treatments while checking for hidden lymphoma, bridging two specialties.
EORTC Cutaneous Lymphoma Tumour Group consensus recommendations address the clinical dilemma of dupilumab use in atopic dermatitis patients where cutaneous lymphoma is suspected, providing a framework to minimize misdiagnosis delays. This fills an important gap between dermatology and hematology practice.
What the study was
- Study design
- Consensus recommendations (expert panel)
- Population
- Atopic dermatitis patients with suspected or confirmed cutaneous lymphoma
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- The Journal of Allergy and Clinical Immunology
Why it surfaced
EORTC consensus recommendations for a common clinical dilemma (AD mimicking cutaneous lymphoma); immediately actionable in dermatology/hematology practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.